TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
TScan Therapeutics, Inc. (TCRX) reported a Q3 loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a $0.28 loss. However, the company missed revenue estimates.
November 12, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TScan Therapeutics reported a Q3 loss of $0.25 per share, better than the expected $0.28 loss, but missed revenue estimates.
The company's EPS was better than expected, which is a positive sign, but missing revenue estimates could offset this. The mixed results may lead to neutral short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100